Differenzierte Therapiestrategie bei Lebermetastasen gastro-entero-pankreatischer Neuroendokriner Neoplasien

Zusammenfassung

Neuroendokrine Neoplasien (NEN) bilden eine heterogene Gruppe maligner Tumoren, die überwiegend dem gastro-entero-pankreatischen System (GEP) zuzuordnen sind. Hierbei sind Dünndarm und Pankreas die häufigsten Organe für Primärtumoren, die Leber stellt den dominanten Metastasierungsort dar. Da viele Patient*innen lange asymptomatisch bleiben, führen oftmals zufällig diagnostizierte Lebermetastasen oder ein Ileus zur Diagnose. Die einzige kurative Therapieoption stellt die komplette Entfernung von Primarius und Metastasen dar. Besonders im Falle der metastasierten Erkrankung sollten die vorhandenen Therapieoptionen immer im interdisziplinären Tumorboard mit Spezialisten*innen aus Gastroenterologie, (Leber-)Chirurgie, Radiologie, Nuklearmedizin, Radiotherapie, Pathologie und Endokrinologie evaluiert werden. Durch die Kombination der verschiedenen Therapieverfahren kann auch für Patient*innen mit fortgeschrittener Erkrankung eine jahrelange Prognose bei guter Lebensqualität erreicht werden. Wichtig für die Therapieentscheidung sind neben patientenindividuellen Faktoren der Differenzierungsgrad des Tumors, dessen hormonelle Sekretion, das Metastasierungsmuster und der Erkrankungsverlauf. Die Behandlung von Lebermetastasen umfasst neben den unterschiedlichen chirurgischen Strategien die lokal-ablativen radiologischen und nuklearmedizinischen Verfahren, die als Ergänzung zu den systemischen Therapien zur Verfügung stehen.

Abstract

Neuroendocrine neoplasias comprise a heterogenous group of malignant tumours, mostly arising from the gastro-entero-pancreatic system (GEP). Most of these tumours develop from the small intestine and pancreas and the liver is the predominant site for distant metastases. Patients may be asymptomatic for a long time and liver metastases are frequently diagnosed by chance or during operations for bowel obstruction, for example, during emergency surgery. The only curative therapy consists in complete removal of primary and metastases. In case of metastatic disease, various treatment modalities need to be discussed in interdisciplinary tumour boards comprised of specialists from gastroenterology, (liver-)surgery, radiology, nuclear medicine, radiotherapy, pathology and endocrinology. By combining different therapies, even patients with progressive disease may reach long-term overall survival with good quality of life. The most important factors for decisions on therapy are individual factors like tumour grading, hormonal functionality, type of metastases and evolution of the disease. Adequate treatment of liver metastases comprises various surgical strategies as well as locally ablative radiological interventions and nuclear medical therapies, in complement to systemic treatments.

Schlüsselwörter

neuroendokrine Neoplasie - neuroendokriner Tumor - lokalablative Therapie - Nuklearmedizin - Lebermetastase

Keywords

liver metastasis - neuroendocrine neoplasia - neuroendocrine tumor - locally ablative therapy - Nuclear medicine

Publication History

Received: 11 February 2022

Accepted after revision: 14 April 2022

Article published online:
15 June 2022

• Literatur

• 1 Dasari A, Shen C, Halperin D. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3: 1335-1342
• 2 Scherübl H, Streller B, Stabenow R. et al. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 2013; 19: 9012-9019
• 3 Pavel M, O’Toole D, Costa F. Vienna Consensus Conference participants. et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016; 103: 172-185
• 4 Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015; 121: 1172-1186
• 5 Norlén O, Stålberg P, Öberg K. et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 2012; 36: 1419-1431
• 6 Frilling A, Modlin IM, Kidd M. Working Group on Neuroendocrine Liver Metastases. et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15: e8-e21
• 7 Frilling A, Li J, Malamutmann E. et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009; 96: 175-184
• 8 Pavel M, Öberg K, Falconi M. ESMO Guidelines Committee. et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 844-860
• 9 Norlén O, Stålberg P, Zedenius J. et al. Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. Br J Surg 2013; 100: 1505-1514
• 10 Selberherr A, Freermann S, Koperek O. et al. Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival?. Orphanet J Rare Dis 2021; 16: 30
• 11 Sham JG, Ejaz A, Gage MM. et al. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. J Gastrointest Surg 2019; 23: 484-491
• 12 Bacchetti S, Pasqual EM, Bertozzi S. et al. Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. Gland Surg 2014; 3: 243-251
• 13 Saxena A, Chua TC, Sarkar A. et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011; 149: 209-220
• 14 Sarmiento JM, Heywood G, Rubin J. et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37
• 15 Feldbrügge L, Wabitsch S, Benzing C. et al. Safety and feasibility of laparoscopic liver resection in patients with a history of abdominal surgeries. HPB (Oxford) 2020; 22: 1191-1196
• 16 Schoening WN, Denecke T, Neumann UP. Präoperative Bildgebung/Operationsplanung für die Leberchirurgie. Chirurg 2015; 86: 1167-1179
• 17 AWMF. Leitlinien-Detailansicht Neuroendokrine Tumore. Registernummer 021–026. https://www.awmf.org/leitlinien/detail/ll/021–026.html
• 18 Pu N, Habib JR, Bejjani M. et al. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021; 9: 329
• 19 Maxwell JE, Sherman SK, O’Dorisio TM. et al. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?. Surgery 2016; 159: 320-333
• 20 Sham JG, Ejaz A, Gage MM. et al. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. J Gastrointest Surg 2019; 23: 484-491
• 21 Makuuchi M, Thai BL, Takayasu K. et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990; 107: 521-527
• 22 Adam R, Laurent A, Azoulay D. et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232: 777-785
• 23 Kianmanesh R, Farges O, Abdalla EK. et al. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg 2003; 197: 164-170
• 24 Schnitzbauer AA, Lang SA, Goessmann H. et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255: 405-414
• 25 Kianmanesh R, Sauvanet A, Hentic O. et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 2008; 247: 659-665
• 26 Linecker M, Kambakamba P, Raptis DA. et al. ALPPS in neuroendocrine liver metastases not amenable for conventional resection – lessons learned from an interim analysis of the International ALPPS Registry. HPB (Oxford) 2020; 22: 537-544
• 27 Elf AK, Andersson M, Henrikson O. et al. Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial. World J Surg 2018; 42: 506-513
• 28 Kennedy A, Bester L, Salem R. NET-Liver-Metastases Consensus Conference. et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) 2015; 17: 29-37
• 29 Scott AT, Breheny PJ, Keck KJ. et al. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery 2019; 165: 166-175
• 30 Chan DL, Dixon M, Law CHL. et al. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases. Ann Surg Oncol 2018; 25: 1768-1774
• 31 Wonn SM, Limbach KE, Pommier SJ. et al. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors. Surgery 2021; 169: 168-174
• 32 Ejaz A, Reames BN, Maithel S. et al. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. HPB (Oxford) 2018; 20: 277-284
• 33 Le Treut YP, Grégoire E, Klempnauer J. ELITA. et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg 2013; 257: 807-815
• 34 Mazzaferro V, Sposito C, Coppa J. et al. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant 2016; 16: 2892-2902
• 35 Machairas N, Daskalakis K, Felekouras E. et al. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021; 34: 130-141
• 36 Norlén O, Daskalakis K, Öberg K. et al. Indication for liver transplantation in young patients with small intestinal NETs is rare?. World J Surg 2014; 38: 742-747
• 37 Cazzato RL, Hubelé F, De Marini P. et al. Liver-Directed Therapy for Neuroendocrine Metastases: From Interventional Radiology to Nuclear Medicine Procedures. Cancers (Basel) 2021; 13: 6368
• 38 Zappa M, Abdel-Rehim M, Hentic O. et al. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol 2012; 7: 107-116
• 39 Akyildiz HY, Mitchell J, Milas M. et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010; 148: 1288-1293
• 40 Kjaer J, Stålberg P, Crona J. et al. Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases. BJS Open 2021; 5: zrab062
• 41 Spiliotis AE, Gäbelein G, Holländer S. et al. Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis. Radiol Oncol 2021; 55: 247-258
• 42 Perrodin SF, Renzulli MM, Maurer MH. et al. Can microwave ablation be an alternative to resection for the treatment of neuroendocrine liver metastases?. Endocr Pract 2020; 26: 378-387
• 43 Schippers AC, Collettini F, Steffen IG. et al. Initial Experience with CT-Guided High-Dose-Rate Brachytherapy in the Multimodality Treatment of Neuroendocrine Tumor Liver Metastases. J Vasc Interv Radiol 2017; 28: 672-682
• 44 Denecke T, Lopez Hänninen E. Brachytherapy of liver metastases. Recent Results Cancer Res 2008; 177: 95-104
• 45 Clift AK, Frilling A. Liver-Directed Therapies for Neuroendocrine Neoplasms. Curr Oncol Rep 2021; 23: 44
• 46 Pitt SC, Knuth J, Keily JM. et al. Hepatic neuroendocrine metastases: chemo- or bland embolization?. J Gastrointest Surg 2008; 12: 1951-1960
• 47 Del Prete M, Fiore F, Modica R. Multidisciplinary Group for NeuroEndocrine Tumors of Naples. et al. Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res 2014; 33: 43
• 48 Riemsma RP, Bala MM, Wolff R. et al. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database Syst Rev 2020; (03) CD009498
• 49 Linch F, Thompson S, Fleming C. et al. Hepatic Artery Embolization for Palliation of Symptomatic Hypoglycemia in Patients With Hepatic Insulinoma Metastases. J Endocr Soc 2021; 5: bvab149
• 50 Starke A, Saddig C, Mansfeld L. et al. Malignant metastatic insulinoma-postoperative treatment and follow-up. World J Surg 2005; 29: 789-793
• 51 Barat M, Cottereau AS, Kedra A. et al. The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med 2020; 9: 2302
• 52 Yao JC, Shah MH, Ito T. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523
• 53 Delaunoit T, Ducreux M, Boige V. et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?. Eur J Cancer 2004; 40: 515-520
• 54 Bodei L, Kwekkeboom DJ, Kidd M. et al. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. Semin Nucl Med 2016; 46: 225-238
• 55 Strosberg J, El-Haddad G, Wolin E. NETTER-1 Trial Investigators. et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376: 125-135
• 56 Hicks RJ, Kwekkeboom DJ, Krenning E. Antibes Consensus Conference participants. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017; 105: 295-309
• 57 Shaheen S, Moradi F, Gamino G. et al. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Curr Treat Options Oncol 2020; 21: 25
• 58 Kolasińska-Ćwikła A, Nowicki ML, Sankowski AJ. et al. Radiological and Clinical Efficacy of Intra-Arterial 90Y-DOTATATE in Patients with Unresectable, Progressive, Liver Dominant Neuroendocrine Neoplasms. J Clin Med 2021; 10: 1794